OpenAlex
PricingAboutJobs
Log inGet started
Work

Proteasome inhibitors and IM iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21

HTML

Year: 2015
Type: article
Study design: Observational Study
Source: European Journal Of Haematology
DOI: 10.1111/ejh.12546
Authors: Hareth Nahi, Thea Kristin Våtsveen, Johan Lund, Bart M.S. Heeg, Birgitte Preiss, Evren Alici, Michael Boe Møller, Karin Fahl Wader, Hanne E.H. Møller, Lill Anny Grøseth, Brian Østergaard, Hong Yan Dai, Erik Holmberg, Gösta Gahrton, Anders Waage, Niels Abildgaard
Institutions: Karolinska Institutet, Norwegian University of Science and Technology, St Olav's University Hospital, University Medical Center Groningen, University of Groningen, Odense University Hospital, University of Gothenburg
Language: English

Topic: Multiple Myeloma Research and Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: proteasome inhibitors, immunomodulators, 1q21 gain, chromosomal abnormalities, high-dose therapy, overall survival, prognostic impact, del(13q), 17p deletion, treatment response, newly diagnosed multiple myeloma
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2146659622
FWCI: 2.658
Cites: 41
Cited by: 43
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security